Effects of Coleus Forskohlii Supplementation on Body Composition and Hematological Profiles in Mildly Overweight Women

Exercise & Sport Nutrition Laboratory, Baylor University, Waco, TX.
Journal of the International Society of Sports Nutrition (Impact Factor: 1.5). 12/2005; 2(2):54-62. DOI: 10.1186/1550-2783-2-2-54
Source: PubMed

ABSTRACT This study investigated the effects of Coleus Forskohlii (CF) on body composition, and determined the safety and efficacy of supplementation.
In a double blind and randomized manner, 23 females supplemented their diet with ForsLeantrade mark (250 mg of 10% CF extract, (n = 7) or a placebo [P] (n = 12) two times per day for 12-wks. Body composition (DEXA), body weight, and psychometric instruments were obtained at 0, 4, 8 & 12 weeks of supplementation. Fasting blood samples and dietary records (4-d) were obtained at 0 and 12-wks. Side effects were recorded on a weekly basis. Data were analyzed by repeated measures ANOVA and are presented as mean changes from baseline for the CF and placebo groups, respectively.
No significant differences were observed in caloric or macronutrient intake. CF tended to mitigate gains in body mass (-0.7 +/- 1.8, 1.0 +/- 2.5 kg, p = 0.10) and scanned mass (-0.2 +/- 1.3, 1.7 +/- 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 +/- 0.7, 1.1 +/- 2.3 kg, p = 0.16), fat free mass (-0.1 +/- 1.3, 0.6 +/- 1.2 kg, p = 0.21), or body fat (-0.2 +/- 1.0, 0.4 +/- 1.4%, p = 0.40). Subjects in the CF group tended to report less fatigue (p = 0.07), hunger (p = 0.02), and fullness (p = 0.04). No clinically significant interactions were seen in metabolic markers, blood lipids, muscle and liver enzymes, electrolytes, red cells, white cells, hormones (insulin, TSH, T3, and T4), heart rate, blood pressure, or weekly reports of side effects.
Results suggest that CF does not appear to promote weight loss but may help mitigate weight gain in overweight females with apparently no clinically significant side effects.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Forskolin is the main ingredient in the Ayurvedic herb Coleus Forskolii. Coleus is a member of mint family and grows mainly in the subtropical arias in India, Burma and Thailand. Forskolin has been used in the treatment of allergies, respiratory problems, cardiovascular disorders, glaucoma, psoriasis, hypothyroidism, weight loss etc. Forskolin increased cyclic AMP and appears to have additional actions that are due to its ability to alter a number of membrane transport proteins. In these review are included a comprehensive account of morphology, distribution, medicinal and cosmetic uses and pharmacological aspects for forskolin.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coleus forskohlii Briq. (Family: Lamiaceae) is a fleshy perennial aromatic herb with fibrous roots that grows under tropical to temperate areas in India, Burma, Thailand, Nepal, Pakistan, Sri Lanka, East Africa and Brazil. The rootstock of the plant is used in Ayurveda and other systems of medicine for several ailments such as heart and lung conditions, asthma, digestive disorder, insomnia, muscle spasm, convulsion and skin diseases. Extensive literature survey was performed based on distribution, morphology, phytochemistry and pharmacological aspects of C. forskohlii through pubmed, scopus, SciFinder, google scholar, sciencedirect and ethnobotanical books. Phytopharmacological knowledge and cosmeceutical use of C. forskohlii and its bioactive constituents have been documented. Coleus roots are exclusive source of forskolin, commonly known as fat burning molecule. It’s unique property is activating of almost all hormone sensitive adenylate cyclase enzymes by cyclic 3′,5′-adenosine monophosphate (cAMP). Other potent compounds are 9-deoxyforskolin (1), 1,9-dideoxyforskolin (2), forskolin I (7), forskolin J (8), forskolin L (9), isoforskolin (16), 1-acetylforskolin (17), forskoditerpenoside A (19), forskoditerpenoside B (20), coleol (21), coleosol (22), 3-hydroxyforskolin (25) etc. Besides well established food and traditional use, clinical evidence indicates its safety assessment and can be taken without any toxic effect. This review covers up to date ethnopharmacological, phytochemical and phytomedical information of C. forskohlii approaching towards its safety and therapeutic perspective.
    Oriental Pharmacy and Experimental Medicine 10/2014; DOI:10.1007/s13596-014-0169-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a major health problem. We investigated the effects of forskolin and rolipram in the diet of animals in which obesity had been induced. We used 50 female albino Wistar rats that were assigned randomly into five groups as follows: group 1, control; group 2, high fat diet; group 3, high fat diet + forskolin; group 4, high fat diet + rolipram; and group 5, high fat diet + rolipram + forskolin. The rats were fed for 10 weeks and rolipram and forskolin were administered during last two weeks. The animals were sacrificed and blood samples were obtained. Serum cAMP, cGMP and free fatty acids (FFA) levels were measured using ELISA assays. We also measured weight gain during the 10 week period. cAMP and FFA levels of groups 3, 4 and 5 were significantly higher than those of groups 1 and 2. We found no significant differences in serum cGMP levels among the groups. The weight gain in groups 3, 4 and 5 was significantly less than for group 2. We also found that the weight gain in group 5 was significantly less than in groups 3 and 4. We found that both forskolin and rolipram stimulated lipolysis and inhibited body weight increase by increasing cAMP levels. Also, combination therapy using the two agents may be more effective in preventing diet induced obesity than either agent alone. We found also that these agents did not effect cellular cGMP levels in diet induced obesity.
    Biotechnic & Histochemistry 02/2014; 89(5). DOI:10.3109/10520295.2014.883463 · 1.00 Impact Factor

Full-text (4 Sources)

Available from
Jun 4, 2014